Nicholas Jason Singer
CIK: 0001828224
Nicholas Jason Singer's purchase track record
Nicholas Jason Singer has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/2/2022 | ERNA | $929K | +11.8% | -39.4% | +5.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ERNA | ▲ Buy | Open Market | 70,822 | $232K | 12/2/2022 | View on chart |
| ERNA | ▲ Buy | Open Market | 212,464 | $697K | 12/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Ernexa Therapeutics reports safety data and new oncology leadership
Ernexa announced that Dr. Robert J. Spiegel has joined the company as a senior executive, strengthening its oncology focus. The company also released safety data from three IND‑enabling studies of its lead iMSC therapy ERNA‑101, showing encouraging results that move the program toward a planned IND filing in Q4 2026. ERNA‑101 was selected for the Emerging Track at the 2026 Cell & Gene Meeting, highlighting its visibility in the cell‑therapy field.
Ernexa Therapeutics reports safety data and new oncology leadership. Ernexa announced that Dr. Robert J. Spiegel has joined the company as a senior executive, strengthening its oncology focus. The company also released safety data from three IND‑enabling studies of its lead iMSC therapy ERNA‑101, showing encouraging results that move the program toward a planned IND filing in Q4 2026. ERNA‑101 was selected for the Emerging Track at the 2026 Cell & Gene Meeting, highlighting its visibility in the cell‑therapy field.